CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
Exendin-(9-39) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00571324
NCT00571324Phase 2Completed
CompareCT.gov

An Open Label Pilot Study of the Effects of the Glucagon-like Peptide-1 Receptor Antagonist, Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

Diva De Leon·interventional·Posted Dec 12, 2007·Updated Dec 11, 2017

In Brief

A Phase 2 clinical trial evaluating Exendin-(9-39) and Vehicle for Congenital Hyperinsulinism. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if Exendin-(9-39), an antagonist of the glucagon-like peptide-1 (GLP-1) receptor with effects on the pancreatic beta cell, increases fasting blood glucose levels in subjects with congenital hyperinsulinism.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongenital Hyperinsulinism
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 12, 2007
Enrollment StartAug 1, 2007
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 18.6 years ago

Interventions

Exendin-(9-39)drug

A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.

Vehicleother

A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.